<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Fearon, William F.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">FFR-Guided PCI Offers Cost-Effective Benefit Compared with Medical Therapy Alone</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">A cost-effectiveness analysis of the Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Therapy (OMT) Versus OMT [FAME 2] trial indicates that FFR-guided PCI is economically viable. The initial cost of FFR-guided PCI is higher than that of medical therapy, but the cost gap narrows by &gt;50% at 1 year.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>